Regeneron 2026 Outlook: DUPIXENT Sales Growth and Expansion Strategies

2026 expectations for DUPIXENT sales growth and expansion indications (per the provided Regeneron 2026 Q1 materials)

1) Baseline: DUPIXENT is already growing strongly in 2026

• In Q1 2026, DUPIXENT net sales were $4.9 billion, up 31% year-over-year on a constant-currency basis. ¹
• Management attributes this growth to broad-based demand across multiple approved indications and geographies and emphasizes that DUPIXENT is supporting its “immunology franchise” foundation. ²¹
• Management also highlights growth across all line indications, including recent launches, and specifically names blockbuster indications such as atopic dermatitis, asthma with nasal polyps, and additional indications (one name is partially indiscernible in the transcript). ¹

2) What “2026 expectations” imply from management’s near-term framing

The excerpts do not provide a formal 2026 year-end numeric sales forecast (e.g., “expected X% growth in 2026”). Instead, they provide directional expectations anchored to (a) strong early-2026 performance and (b) continued indicator expansion and patient runway.

• Management states they are “well positioned for sustained growth over the near and long term,” citing nearly $20 billion annualized global net sales and “significant room for further market penetration across indications.” ¹
• In the Q1 2026 prepared remarks, management characterizes DUPIXENT as delivering “double-digit growth” in the context of “strong commercial execution across our key growth products,” with DUPIXENT global net sales up 31% in the quarter. ²

Bottom line from the excerpts: the expectation for 2026 is continuation of high growth momentum rather than a specific quantified forecast, supported by strong demand and ongoing penetration of a broadening label/indication set. ²¹

3) Expansion indications: what’s already expanding the eligible patient population (and therefore sales growth runway)

The transcript indicates multiple “expansion” mechanisms: new approvals in the U.S., launches in new disease areas, and broader age coverage—all of which management ties to additional patient opportunity.

A) Indication expansions and younger age coverage

• Allergic fungal rhinosinusitis (AFRS): DUPIXENT was recently approved in the U.S. as the first/only medicine for AFRS in adults and children 6 years and older. ³
• Chronic spontaneous urticaria (CSU) pediatric expansion: DUPIXENT was approved in the U.S. and Europe for children 2 to 11 years old, expanding beyond adolescents/adults. ³

Management explicitly connects these approvals to “an expanding role of DUPIXENT across diseases…and across a broad range of ages,” reinforcing that the product’s growth runway is not limited to the original core indications. ³

B) Uptake across newly launched indications (explicit examples)

Management cites strong uptake across multiple more recent launches, including:

• COPD
• chronic spontaneous urticaria
• polyps (context suggests nasal polyps)
• allergic fungal rhinosinusitis ¹

These are presented as evidence that the label/coverage additions are translating into demand growth across a widening disease portfolio. ¹

4) The longer-run “expansion indication” strategy that supports 2026 expectations

While the question asks about 2026 expectations, the excerpts also explain management’s longer-term “life cycle expansion” approach for DUPIXENT—relevant because it helps contextualize continued growth assumptions through 2026.

• Management discusses a life cycle strategy focused on leveraging immunology and a large pipeline (“nearly 50 things in the pipeline”), emphasizing extended-interval IL-13/IL-4 and new diseases not yet covered. ⁴
• Management also indicates development of next-generation approaches including long-acting antibodies and bispecifics, and states they are “on track to initiate a first-in-human trial” for an IL-13 antibody by the middle of this year (2026). ³
• Regarding why this matters, management’s discussion frames these efforts as enabling continued leadership even as DUPIXENT’s underlying patent life could evolve—i.e., not assuming a simple replacement but instead expanding the franchise. ⁴

5) Consolidated answer to the question

Expectations for DUPIXENT sales growth in 2026 (from the excerpt set):

• The excerpt set supports an expectation of continued strong growth, evidenced by 31% constant-currency Q1 growth to $4.9B and management’s characterization of DUPIXENT as well-positioned for sustained growth. ²¹

Expectations for DUPIXENT expansion indications in 2026 (from the excerpt set):

• The excerpt set supports expansion through additional approved indications and broader eligible patient populations, explicitly including:
  • AFRS approval for adults and children 6+ (U.S.). ³
  • CSU pediatric expansion to ages 2–11 (U.S. and Europe). ³
  • Continued uptake across COPD, CSU, nasal polyps/polyps, and AFRS as recently launched indications. ¹

Notably: the excerpts do not specify a list of new 2026 regulatory approvals with dates beyond what is already described as “recently approved” / launched in the materials. ³¹

---